PLoS One
March 6, 2026
Caden Poh, Cheyanne Head, John-Jose Nunez et al.
1 citation
Bipolar disorder (BD) is a prevalent mood disorder that can be associated with serious personal, societal, and economic costs. Growing attention is being paid to the importance of including the experiences of people living with BD in research and healthcare system advancement. However, there is still much to be learned about what people with BD are prioritizing, and where their needs are not...
Psychopharmacology
August 1, 2024
Kimberly Sakai, Ellen Bradley, Joseph A. Zamaria et al.
10 citations
Treatments with the serotonergic psychedelic psilocybin are being investigated for multiple neuropsychiatric disorders. Because many patients with these disorders use selective serotonin reuptake inhibitors (SSRIs), understanding interactions between psilocybin and SSRIs is critical for evaluating the safety, efficacy, and scalability of psilocybin-based treatments. Current knowledge about...
Journal of Psychopharmacology
July 1, 2023
Emma Morton, Kimberly Sakai, Amir Ashtari et al.
Braillon A (2011) The many moral responsibilities of independent datamonitoring committees. Am J Bioeth 11: 16–17. Council for International Organizations of Medical Sciences (1999) Guidelines for preparing core clinical-safety information on drugs second edition – Report of CIOMS working groups III and V. Geneva: Council for International Organizations of Medical Sciences. Huxley A (1961) US...
Journal of Psychopharmacology
December 14, 2022
Emma Morton, Kimberly Sakai, Amir Ashtari et al.
75 citations
Background: Psilocybin, the primary psychoactive component of psychedelic ‘magic mushrooms’, may have potential for treating depressive symptoms, and consequent applications for bipolar disorder (BD). Knowledge of the risks and benefits of psilocybin in BD is limited to case studies. Aim: To support the design of clinical trials, we surveyed experiences of psilocybin use in people with BD....
PLoS One
December 14, 2022
Meghan DellaCrosse, Mollie Pleet, Emma Morton et al.
28 citations
Objectives People with bipolar disorder (BD) spend more time depressed than manic/hypomanic, and depression is associated with greater impairments in psychosocial functioning and quality of life than mania/hypomania. Emerging evidence suggests psilocybin, the psychoactive compound in “magic mushrooms,” is a promising treatment for unipolar depression. Clinical trials of psilocybin therapy have...